At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 06:35 ET
Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R&D spending increased to $83.6M. The clinical-stage biotech reiterated key PDUFA milestones (zidesamtinib September 18, 2026) and submitted its NDA for neladalkib, but with no revenue and rising operating expenses, the quarter itself was a routine cash-burn update with no fundamental catalyst.
- Net loss of $109.3M for Q1 2026, vs $84.6M in Q1 2025
- Cash, cash equivalents and marketable securities of $1.3B as of March 31, 2026, down from $1.4B at year-end 2025
- R&D expenses of $83.6M in Q1 2026, up from $74.4M in Q1 2025
- G&A expenses of $35.8M in Q1 2026, up from $20.4M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access